NSE: PPLPHARMA · 28 October 2026
- Piramal Pharma has risen 18.36% over 2 trading sessions; today's move is +16.24%.
- Piramal Pharma reported its financial results for the quarter and half year ended September 30, 2026, showing consolidated revenue of ₹2,617 crores for Q2 FY27, up 28% year-on-year. EBITDA for the quarter rose 72% year-on-year to ₹385 crores with margins expanding over 350 basis points to 14.7%. Buoyed by strong first-half momentum, management upgraded its FY27 revenue growth outlook to 19% to 20% with higher profitability.
- Trading volume was 50.00 times the 20-day average daily volume.
Piramal Pharma share price: 18.36% rise over 2 trading sessions
Piramal Pharma Ltd. (PPLPHARMA) shares surged sharply today, trading up 16.24% at ₹231.00 compared to their previous close of ₹198.72. The stock opened at ₹214.10 and climbed to a day's high of ₹235.38 while touching a low of ₹209.04.
The broader market exhibited mild weakness, with the Nifty falling 0.22%, while the thematic Nifty Pharma sector index advanced 1.04%. Against this backdrop, Piramal Pharma outperformed both the benchmark index and its sector peers, building on a robust 5-day return of 20.82% and a 20-day return of 11.82%.
The strong price action coincides with the release of the company's financial results for the second quarter and half year ended September 30, 2026, announced on October 27, 2026. Management reported a 28% year-on-year rise in consolidated revenue from operations to ₹2,617 crores for Q2 FY27 and a 72% jump in EBITDA to ₹385 crores, supported by robust performance across its CDMO, Complex Hospital Generics, and Consumer Healthcare businesses alongside an upgrade to its full-year FY27 guidance.
11.62 crore shares traded by 28 October 2026 · 03:25 PM IST. This compares with a 20-day average daily volume of 23.24 lakh shares (50.00 times). The five-day average daily volume was 25.62 lakh shares. Separately, the NSE report for 27 October 2026 showed 12.72 lakh shares delivered, representing 44.25% of that day’s traded volume. The same report recorded 40,081 trades.
The sharp rally in Piramal Pharma shares is directly supported by the release of Q2 FY27 financial results showing a 28% increase in operational revenue, a 72% surge in EBITDA, and an upgraded full-year outlook.
Latest Company Developments
Piramal Pharma reported its financial results for the quarter and half year ended September 30, 2026, showing consolidated revenue of ₹2,617 crores for Q2 FY27, up 28% year-on-year. EBITDA for the quarter rose 72% year-on-year to ₹385 crores with margins expanding over 350 basis points to 14.7%. Buoyed by strong first-half momentum, management upgraded its FY27 revenue growth outlook to 19% to 20% with higher profitability.
The earnings beat and guidance upgrade provide fundamental backing for investor sentiment and valuation re-rating.
The company announced that its sales and distribution support commercial arrangement with Bayer Pharmaceuticals Private Limited will conclude upon its natural expiry on December 31, 2026, and will not be renewed. Piramal Pharma noted that the arrangement accounts for less than 5% of consolidated revenue and expects no material impact on profitability or financial position.
Clarifies the upcoming transition of a minor distribution contract without posing material earnings risks.
In response to an exchange clarification request regarding a media report about a $1.7 million investment from the Government of Ontario for its Aurora facility, the company confirmed the funding support under the LSSUF program. It clarified that the grant aims to support infrastructure upgrades and operational efficiency, though it does not constitute a material event under listing regulations.
Resolves exchange queries regarding regional operational grants without altering near-term financial expectations.
a press release dated October 27, 2026, titled "Piramal Pharma Limited Announces Results for Q2 and H1 FY2".
Piramal Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Ownership & Transaction Activity
Mutual Fund Holdings
Mutual funds held 12.71% on 30 September 2026. This compares with 13.18% on 30 June 2026, a change of -0.47 percentage points.
The filing reported 27 MF/UTI holders.
What to Watch Next
- Execution of order inflows and capacity utilization across the CDMO business segments
- Integration progress and revenue contribution of the Kenalog product acquisition
- Transition management and business continuity following the impending expiry of the Bayer distribution agreement
- Sustained delivery volumes and liquidity levels relative to the 20-day average volume
More Piramal Pharma news and dated analysis →
Frequently Asked Questions
What is the latest Piramal Pharma company news?
Piramal Pharma reported its financial results for the quarter and half year ended September 30, 2026, showing consolidated revenue of ₹2,617 crores for Q2 FY27, up 28% year-on-year. EBITDA for the quarter rose 72% year-on-year to ₹385 crores with margins expanding over 350 basis points to 14.7%. Buoyed by strong first-half momentum, management upgraded its FY27 revenue growth outlook to 19% to 20% with higher profitability.
How strong was Piramal Pharma’s trading volume?
11.62 crore shares traded, 50.00 times the 20-day average daily volume. The price and volume data are dated 28 October 2026 · 03:25 PM IST.
Do the mutual-fund figures show buying today?
They show holdings on 30 September 2026. Quarterly holdings do not identify purchases made on the article date.
Research & analysis: WittyTrades Research Desk
Reviewed by: Mohanish Sanghavi — SEBI Registered Research Analyst
Disclaimer: Investments in securities markets are subject to market risks. Registration with SEBI and NISM certification do not guarantee performance or returns. This article is for information and education, not personalised investment advice or a recommendation to buy, sell or hold.